Technical Analysis for ACXP - Acurx Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 20 DMA Support | Bullish | 7.66% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 22 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
| Up 10% | about 23 hours ago |
| Up 1 ATR | about 23 hours ago |
| Rose Above 50 DMA | about 23 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.82 |
| 52 Week Low | 1.17 |
| Average Volume | 76,460 |
| 200-Day Moving Average | 2.89 |
| 50-Day Moving Average | 2.18 |
| 20-Day Moving Average | 2.08 |
| 10-Day Moving Average | 2.08 |
| Average True Range | 0.17 |
| RSI (14) | 57.98 |
| ADX | 16.83 |
| +DI | 25.51 |
| -DI | 17.70 |
| Chandelier Exit (Long, 3 ATRs) | 1.86 |
| Chandelier Exit (Short, 3 ATRs) | 2.02 |
| Upper Bollinger Bands | 2.24 |
| Lower Bollinger Band | 1.92 |
| Percent B (%b) | 1.02 |
| BandWidth | 15.78 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.0284 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.58 | ||||
| Resistance 3 (R3) | 2.58 | 2.47 | 2.53 | ||
| Resistance 2 (R2) | 2.47 | 2.39 | 2.47 | 2.51 | |
| Resistance 1 (R1) | 2.36 | 2.33 | 2.42 | 2.36 | 2.49 |
| Pivot Point | 2.25 | 2.25 | 2.28 | 2.25 | 2.25 |
| Support 1 (S1) | 2.14 | 2.17 | 2.20 | 2.14 | 2.01 |
| Support 2 (S2) | 2.03 | 2.11 | 2.03 | 1.99 | |
| Support 3 (S3) | 1.92 | 2.03 | 1.98 | ||
| Support 4 (S4) | 1.92 |
